Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:02 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 535 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Health Tag Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

NCT06038617
View directory record Official record
Conditions
Fever After Vaccination, Fever, Seizures Fever
Interventions
mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 1, 2026, 10:02 PM EST
Terminated Phase 2 Interventional Results available

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

NCT03780543
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 71 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 4 Interventional

Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder

NCT00208741
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Gabitril
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
Atlanta, Georgia • Long Island City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 3 Interventional Results available

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

NCT02369874
View directory record Official record
Conditions
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Interventions
MEDI4736, MEDI4736 + Tremelimumab, Standard of Care
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
23
States / cities
Tucson, Arizona • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 1 Interventional

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

NCT01276496
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Nov 1, 2026, 10:02 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Weight Discrimination and Poor Cardiovascular Health

NCT05714696
View directory record Official record
Conditions
Obesity
Interventions
Weight discrimination experience, Control experience
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

NCT00388596
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2008 · Synced Nov 1, 2026, 10:02 PM EST
Completed Not applicable Interventional

Open-Label Placebos to Treat Fatigue in Multiple Sclerosis

NCT04002102
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
OLP treatment, Usual care, Expectancy Group
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

NCT05890586
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
91
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 1 Interventional

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

NCT02631044
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma
Interventions
JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 1 Interventional

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

NCT03918278
View directory record Official record
Conditions
Neoplasms
Interventions
MK-0482, pembrolizumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Detroit, Michigan • Hackensack, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 4 Interventional Results available

Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

NCT02586506
View directory record Official record
Conditions
Asthma
Interventions
Placebo ELLIPTA inhaler, Questionnaire
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Nov 1, 2026, 10:02 PM EST
Enrolling by invitation Not applicable Interventional

Virtual Lifestyle Intervention for Weight Management and Cardiovascular Heal

NCT07572721
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Multicomponent Virtual Lifestyle Intervention
Behavioral
Lead sponsor
Truemedicine Inc
Other
Eligibility
30 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 3 Interventional

De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

NCT06001320
View directory record Official record
Conditions
Kidney Transplant; Complications, CMV
Interventions
Letermovir 480 mg once daily, Historical/Control
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 1 Interventional

Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors

NCT01111097
View directory record Official record
Conditions
Brain Tumor, Glioblastoma
Interventions
Dichloroacetate
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Nov 1, 2026, 10:02 PM EST
Not listed Not applicable Interventional

Study to Evaluate the Reliability, Validity and Safety of Subjective Mobile Refraction

NCT05049070
View directory record Official record
Conditions
Refractive Errors
Interventions
Mobile medical application to self administer a subjective refraction test, Standard of care refraction test
Diagnostic Test
Lead sponsor
1800 Contacts, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • Petaluma, California • Pomona, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 1Phase 2 Interventional

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT01713738
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP)
Interventions
rituximab
Drug
Lead sponsor
Neufeld, Ellis J, MD, PhD
Individual
Eligibility
18 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 4 Interventional Results available

Home Based Daratumumab Administration for Patients With Multiple Myeloma

NCT05511428
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life Assessment, Interview
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 1, 2026, 10:02 PM EST
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

NCT06086626
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Up to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 1, 2026, 10:02 PM EST
Recruiting Phase 2 Interventional

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

NCT06660368
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 1, 2026, 10:02 PM EST
Terminated Phase 2 Interventional Results available

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

NCT02448810
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
BAX69 + infusional 5-FU/LV, BAX69 + panitumumab, BAX69 + 5-FU/LV, Standard of Care, Standard of Care
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Port Saint Lucie, Florida • Joliet, Illinois • Goshen, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Nov 1, 2026, 10:02 PM EST
Completed Not applicable Interventional

Gold Factor on Knee Joint Health and Function

NCT05347602
View directory record Official record
Conditions
Knee Arthritis, Knee Osteoarthritis, Knee Pain Chronic, Knee Discomfort, Rheumatoid Arthritis, Knee Pain Swelling
Interventions
Gold Factor (Gold Nanoparticles, AuNPs), Placebo
Dietary Supplement
Lead sponsor
4Life Research, LLC
Industry
Eligibility
18 Years to 87 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Nov 1, 2026, 10:02 PM EST
Suspended Not applicable Interventional

Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression

NCT01794559
View directory record Official record
Conditions
Depressive Disorder
Interventions
PEER Interactive Report
Device
Lead sponsor
MYnd Analytics
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Nov 1, 2026, 10:02 PM EST
Withdrawn Phase 3 Interventional

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

NCT03532022
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, Standard Care
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Morehead City, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 10:02 PM EST